Otsuka Holdings Co., Ltd. OTSKY
36.97 USD -0.26 (-0.70%)
Nov 3, 2026, 3:08 PM EST
36.97 Day range 37.21
26.11 52-week range 40.92
- YTD
- +30.50%
- 1 year
- +36.93%
- Market cap
- 38.74B
- EPS (ttm)
- 2.33
- P/E ratio
- 15.87
- YTD return
- +30.50%
- 1-year return
- +36.93%
- Volume
- 2.22K
- Avg volume
- 44.40K
- Open
- 37.12
- Previous close
- 37.23
- Day's range
- 36.97 – 37.21
- 52-week range
- 26.11 – 40.92
- Earnings date
- Oct 30, 2026
6M +1.45 (+4.08%)
Next earnings
Oct 30, 2026
Expected Oct 30, 2026. Consensus EPS estimate 0.56.
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Oct 30, 2026 | Sep 30, 2026 | 0.56 | — | — | — |
| Jul 31, 2026 | Jun 30, 2026 | 0.506 | 0.70 | +0.19 | +38.34% |
| Apr 29, 2026 | Mar 31, 2026 | 0.4306 | 0.583 | +0.15 | +35.39% |
| Feb 12, 2026 | Dec 31, 2025 | 0.2377 | 0.4057 | +0.17 | +70.68% |
| Oct 31, 2025 | Sep 30, 2025 | 0.515 | 0.797 | +0.28 | +54.76% |
| Apr 30, 2025 | Mar 30, 2025 | 0.3947 | 0.556 | +0.16 | +40.87% |
News
Contrasting Otsuka (OTCMKTS:OTSKY) & Lyra Therapeutics (OTCMKTS:LYRA) 
Otsuka (OTCMKTS:OTSKY) Shares Gap Down – Here’s Why 
Critical Survey: Inhibikase Therapeutics (NASDAQ:IKT) and Otsuka (OTCMKTS:OTSKY) 
Otsuka, Ionis' experimental ALS drug meets main goal in late-stage study 
Otsuka Announces Transformative Phase 3 FUSION Results for Ulefnersen, Bringing the FUS-ALS Community Closer to a Potential Targeted Treatment 
Otsuka Holdings Co., Ltd. (OTSKY) Discusses 24-Month eGFR Results of Sibeprenlimab in IgA Nephropathy from Phase III VISIONARY Study Prepared Remarks Transcript 
Otsuka Holdings Co., Ltd. (OTSKY) Q2 2026 Earnings Call Prepared Remarks Transcript 
Aristotle Global Equity Advisory Q2 2026 Portfolio Review 
Otsuka ICU Medical LLC Announces Over $500M Expansion of IV Solutions Manufacturing in North America 
AstraZeneca (OTCMKTS:AZNCF) versus Otsuka (OTCMKTS:OTSKY) Financial Review
Your note
Sign in to keep a note on OTSKY — it syncs with the Stock Master app.